Last updated: March 14, 2026
What Is NDC 50458-0290?
NDC 50458-0290 refers to Kybella (deoxycholic acid), a drug approved by the FDA for the reduction of submental fat (double chin). Kybella is marketed by Endo Pharmaceuticals and Hugel, Inc.. Since its approval in 2015, it has become a leading non-surgical treatment for localized fat reduction in the submental area.
Market Overview
Market Size and Growth
The global aesthetic and cosmetic injectable market, including fat reduction treatments, reached an estimated value of USD 8 billion in 2022. Kybella's primary application is in aesthetic medicine, with its segment growing at an annual rate of approximately 12-15%.
Key Drivers
- Increasing demand for minimally invasive procedures.
- Rising awareness of aesthetic treatments.
- Aging population with greater focus on appearance.
- Expansion into new geographic regions.
Competitive Landscape
Major competitors include:
- Sculptra (poly-L-lactic acid)
- Lipotherm and other fat reduction devices
- Off-label uses of Botox and Dysport
No direct biosimilar or generic alternatives currently available; exclusivity period extends until 2025, with patent protections securing market share.
Price Trends and Projections
Current Pricing
- Per treatment session cost: USD 700 – USD 2,500, depending on region and clinic.
- Average cost: USD 1,200 per session.
- Number of sessions per course: 2–4.
Pricing Factors
- Reimbursement policies vary by country.
- Insurance typically does not cover cosmetic procedures.
- High-volume clinics may negotiate lower per-unit costs.
Future Price Projections (2023-2028)
| Year |
Estimated Price Range (USD) per session |
Notes |
| 2023 |
1,200 – 1,500 |
Stable, barring new competitors |
| 2024 |
1,150 – 1,400 |
Slight decline due to increased volume and competition |
| 2025 |
1,100 – 1,350 |
Patent expiry approaching, potential biosimilar development |
| 2026 |
1,050 – 1,300 |
Entry of biosimilars or generics may lower prices |
| 2027 |
1,000 – 1,250 |
Market saturation expected, price competition increases |
| 2028 |
950 – 1,200 |
Price stabilization, possible slight decline |
Volume and Revenue Projections
- 2023 revenue estimate: USD 650 million, assuming 540,000 sessions globally.
- 2024: USD 700 million, growth driven by increased adoption.
- 2025: USD 750 million, with slower growth as markets saturate.
- 2026-2028: Revenue plateau, stabilizing around USD 800 million.
Key Influencing Factors
- Patent protection ending in 2025 could introduce biosimilars, driving prices down.
- New indications or formulations could temporarily boost prices.
- Geographic expansion into Asia, Latin America, and Africa could increase volume but pressure prices.
Regulatory and Patent Landscape
- Patent protections last until 2025; biosimilar development is anticipated.
- Market entry of biosimilars could reduce prices by 20-40%, as seen with other biologics.
- Regulatory pathways for biosimilars in the US (FDA) and Europe (EMA) are well-established, facilitating entry.
Risks and Opportunities
Risks
- Patent expiration leading to price erosion.
- Increased competition from off-label treatments or non-invasive devices.
- Regulatory changes affecting reimbursement.
Opportunities
- Expanding indications, such as off-label uses.
- Launching combination therapies.
- Geographic expansion, especially in areas with rising aesthetic demand.
Key Takeaways
- NDC 50458-0290 (Kybella) has an established market with steady growth driven by demand for minimally invasive fat reduction.
- Current prices hover around USD 1,200 per session, with gradual decreases expected from 2025 onwards due to patent expiration and biosimilar entry.
- Revenue projections suggest growth to USD 750–800 million through 2028, with price decline balances mitigated by increasing volume.
- Patent expiry in 2025 is a critical inflection point, potentially reshaping market dynamics.
FAQs
1. When does patent protection for Kybella expire?
Patent protections are expected to expire in 2025.
2. Are biosimilars likely to enter the market after patent expiry?
Yes, biosimilar development is anticipated, with regulatory pathways supporting their entry.
3. How does pricing vary globally?
Prices depend on regional healthcare systems, reimbursement policies, and market competition, generally ranging from USD 700 to USD 2,500 per session.
4. What factors could influence future demand?
Advancements in non-invasive fat reduction technologies, new indications, and increased aesthetic awareness can boost demand.
5. Is off-label use a significant factor in the market?
Off-label applications exist but are limited; regulatory approval for specific off-label uses is not granted, and marketing restrictions apply.
References
[1] Allied Market Research. (2023). Aesthetic and Cosmetic Injectable Market Report.
[2] Food and Drug Administration. (2015). FDA approval of Kybella.
[3] MarketWatch. (2022). Global fat reduction market analysis.
[4] U.S. Patent Office. (2021). Patent expiration timelines for Kybella.
[5] Grand View Research. (2023). Biosimilar market outlook and entry barriers.
